New drug combo tested to control Tough-to-Treat breast cancer

NCT ID NCT06369285

Recruiting now Disease control Sponsor: Puma Biotechnology, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding an experimental drug called alisertib to standard hormone therapy can better control advanced breast cancer that has stopped responding to previous hormone treatments. It will enroll about 150 adults whose cancer has returned or spread and aims to find the best dose and see which patients might benefit most. The main goals are to see if the combination shrinks tumors, delays cancer growth, and is safe for patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Alabama Oncology
RECRUITING

Birmingham, Alabama, 34235, United States
Alliance Cancer Specialists
RECRUITING

Horsham, Pennsylvania, 19044, United States
Beverly Hills Cancer Center
RECRUITING

Beverly Hills, California, 90211, United States
Cancer Care Specialists
RECRUITING

Reno, Nevada, 89511, United States
Cancer Specialists of North Florida
RECRUITING

Jacksonville, Florida, 32256, United States
City of Hope at Orange County Lennar Foundation Cancer Center
RECRUITING

Irvine, California, 92618, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Fundación Instituto Valenciano de Oncología (IVO)
RECRUITING

Valencia, 46009, Spain
Fundação Champalimaud
RECRUITING

Lisbon, 1400-038, Portugal
Hospital CUF Descobertas
RECRUITING

Lisbon, 1998-018, Portugal
Hospital Clínico Universitario de Valencia
RECRUITING

Valencia, 46010, Spain
Hospital Clínico de Barcelona
RECRUITING

Barcelona, 08036, Spain
Hospital General Universitario Dr. Balmis
RECRUITING

Alicante, 03010, Spain
Hospital San Cecilio
RECRUITING

Granada, 18012, Spain
Hospital San Pedro de Alcántara
RECRUITING

Cáceres, 10003, Spain
Hospital Universitario Arnau de Vilanova
RECRUITING

Lleida, 25198, Spain
Hospital Universitario Fundación Jiménez Díaz
RECRUITING

Madrid, 28040, Spain
Hospital Universitario Juan Ramon Jimenez
RECRUITING

Huelva, 21005, Spain
Hospital Universitario Vall d'Hebron
RECRUITING

Barcelona, 08035, Spain
Hospital Universitario Virgen del Rocío
RECRUITING

Seville, 41013, Spain
Hospital Universitario de Basurto
RECRUITING

Bilbao, 48013, Spain
Hospital Universitario de Cruces
RECRUITING

Barakaldo, 48903, Spain
Hospital Universitario de Jaén
RECRUITING

Jaén, 23007, Spain
Instituto Português Oncologia Do Porto
RECRUITING

Porto, 4200-072, Portugal
Instituto Português de Oncologia de Lisboa Francisco Gentil (IPO Lisboa)
RECRUITING

Lisbon, 1099-023, Portugal
LA Cancer Network
RECRUITING

Los Angeles, California, 90017, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
Mayo Clinic Florida
RECRUITING

Jacksonville, Florida, 32224, United States
Mayo Clinic Hospital
RECRUITING

Phoenix, Arizona, 85054, United States
MemorialCare Orange Coast Medical Center
RECRUITING

Fountain Valley, California, 92708, United States
Missouri Cancer Associates
RECRUITING

Columbia, Missouri, 65201, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Oncology Hematology Associates
RECRUITING

Springfield, Missouri, 65807, United States
Saint Luke's Cancer Institute
RECRUITING

Kansas City, Missouri, 64111, United States
Taylor Cancer Research Center
RECRUITING

Maumee, Ohio, 43537, United States
Tennessee Oncology, Greco-Hainsworth Center for Research
RECRUITING

Nashville, Tennessee, 37203, United States
Texas Oncology
RECRUITING

Dallas, Texas, 75246, United States
The Ohio State University, Stefanie Spielman Comprehensive Breast Center
RECRUITING

Columbus, Ohio, 43212, United States
The University of Chicago
RECRUITING

Chicago, Illinois, 60637, United States
UCLA Department of Medicine - Hematology/Oncology
RECRUITING

Los Angeles, California, 90095, United States
UNC Hospitals, University of North Carolina at Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27514, United States
University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
RECRUITING

San Francisco, California, 94158, United States
University of Colorado School of Medicine
RECRUITING

Aurora, Colorado, 80045, United States
University of Illinois Cancer Center
RECRUITING

Chicago, Illinois, 60612, United States
University of Minnesota, Masonic Cancer Center
RECRUITING

Minneapolis, Minnesota, 55455, United States
University of Pennsylvania, Abramson Cancer Center, Perelman Center for Advanced Medicine
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
University of Pittsburgh (UPMC)
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States
University of Rochester Medical Center
RECRUITING

Rochester, New York, 14642, United States
Virginia Cancer Institute
RECRUITING

Richmond, Virginia, 23229, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States
Winship Cancer Institute, Emory University
RECRUITING

Atlanta, Georgia, 30322, United States
Yale University, Yale Cancer Center
WITHDRAWN

New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.

HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER METASTATIC BREAST CANCER RECURRENT BREAST CANCER